Sjögren's syndrome

A Clinician's Pearls and Myths in Rheumatology

Volumn , Issue , 2009, Pages 107-130

  Ramos Casals, Manuel ^a   Daniels, Troy E ^b   Fox, Robert I ^c   Whitcher, John P ^d   Fragoulis, George E ^e   Skopouli, Fotini N ^e   Moutsopoulos, Haralampos M ^e  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SCRIPPS MEMORIAL HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865704343     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-84800-934-9_12     Document Type: Chapter

References (146)

1. Abraham CM, al-Hashimi I, Haghighat N. Evaluation of the levels of oral Candida in patients with Sjögren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;86:65-8
2. Alexander E, Arnett F, Provost T, Stevens MB. Sjögren's syndrome: association of anti-Ro(SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperactivity. Ann Intern Med. 1983;98:155-9
3. Alexander EL, Beall SjS, Gordon B, et al Magnetic resonance imaging of cerebral lesions in patients with the Sjögren syndrome. Ann Intern Med. 1988;108:815-23
4. Almstahl A, Kroneld U, Tarkowski A, Wikstrom M. Oral microbial flora in Sjögren's syndrome. J Rheumatol. 1999;26:110-4
5. Andonopoulos AP, Drosos AA, Skopouli FN, Acritidis NC, Moutsopoulos HM. Secondary Sjögren's syndrome in rheumatoid arthritis. J Rheumatol. 1987;14:1098-103
6. Andonopoulos AP, Drosos AA, Skopouli FN, Moutsopoulos HM. Sjögren's syndrome in rheumatoid arthritis and progressive systemic sclerosis. A comparative study. Clin Exp Rheumatol. 1989;7: 203-5
7. Aoki N. Klinefelter's syndrome, autoimmunity, and associated endocrinopathies. Intern Med. 1999;38:838-9
8. Atalar K, Afzali B, Lams B, et al Falls, hypokalaemia, and a dry mouth. Lancet. 2007;370(9582):192
9. Belafsky PC, Postma GN. The laryngeal and esophageal manifestations of Sjögren's syndrome. Curr Rheumatol Rep. 2003;5:297-303
10. Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ. Sjögren's syndrome. A clinical, pathological, and serological study of sixty-two cases. Medicine (Baltimore). 1965;44:187-231
11. Boki KA, Ioannidis JP, Segas JV, et al How significant is sensorineural hearing loss in primary Sjögren's syndrome? J Rheumatol. 2001;28: 798-801
12. Bossini N, Savoldi S, Franceschini F, et al Clinical and morphological features of kidney involvement in primary Sjögren's syndrome. Nephrol Dial Transplant. 2001;16:2328-36
13. Boutsi EA, Paikos S, Dafni UG, et al Dental and periodontal status of Sjögren's syndrome. J Clin Periodontol. 2000;27:231-5
14. Bowman SK, Ibrahim GH, Holmes G, et al Estimating the prevalence among Caucasian women of primary Sjögren's syndrome in two general practices in Birmingham, UK Scand J Rheumatol. 2004;33: 39-43
15. Brito-Zerón P, Ramos-Casals M, Bove A, et al Predicting adverse outcomes in primary Sjögren's syndrome: identification of prognostic factors. Rheumatology (Oxford). 2007;46(8):1359-62
16. Brito-Zerón P, Ramos-Casals M, Nardi N, et al Circulating monoclonal immunoglobulins in Sjögren syndrome: prevalence and clinical significance in 237 patients. Medicine (Baltimore). 2005;84(2): 90-7
17. Brito-Zerón P, Soria N, Munoz S, et al Prevalence and clinical relevance of autoimmune neutropenia in patients with primary Sjögren's syndrome. Semin Arthritis Rheum. 2008;38(5):389-95
18. Caporali R, Bonacci E, Epis O, et al Safety and usefulness of minor salivary gland biopsy: retrospective analysis of 502 procedures performed at a single center. Arthritis Rheum. 2008;59:714-20
19. Chai J, Herrmann DN, Stanton M, et al Painful small-fi ber neuropathy in Sjögren's syndrome. Neurology. 2005;65:925-7
20. Collard RC, Koehler RP, Mattson DH. Frequency and significance of antinuclear antibodies in multiple sclerosis. Neurology. 1997;49: 857-61
21. Coppo P, Sibilia J, Maloisel F, et al Primary Sjögren's syndrome associated agranulocytosis: a benign disorder? Ann Rheum Dis. 2003;62: 476-8
22. Cummings NA, Schall GL, Asofski R. Sjögren's syndrome. New aspects of research, diagnosis and therapy. Ann Intern Med. 1971;75: 937
23. Dafni UG, Tzioufas AG, Staikos P, et al Prevalence of Sjögren's syndrome in a closed rural community. Ann Rheum Dis. 1997;56: 521-5
24. Daniels T, Greenspan JS, Cox D, Criswell LA, DeSouza Y, Dong Y, et al Objective measures in Sjögren's syndrome are strongly associated with each other but not with sicca symptoms: analysis of 564 enrollees in the SICCA international registry and repository Arthritis Rheum. 2007 56 Suppl: S446
25. Daniels T, Whitcher J. Association of patterns of labial salivary gland infl ammation with keratoconjunctivitis sicca. Analysis of 618 patients with suspected Sjögren's syndrome. Arthritis Rheumatol. 1994;37:869-77
26. Daniels TE. Benign lymphoepithelial lesion and Sjögren's syndrome. Ch 6. In Ellis GL, Auclair PL, Gnepp DR, editors. Surgical pathology of the salivary glands. Philadelphia: W.B.Saunders; 1991. p. 83-106
27. Daniels TE, Fox PC. Salivary and oral components of Sjögren's syndrome. Rheum Dis Clin North Am. 1992;18(3):571-89
28. Daniels TE, Silverman S, Michalski JP, Greenspan JS, Sylvester RA, Talal N. The oral component of Sjögren's syndrome. Oral Surg Oral Med Oral Pathol. 1975;39:875-85
29. Daniels TE. Evaluation, differential diagnosis, and treatment of xerostomia. J Rheumatol. 2000;27(Suppl 61):6-10
30. Davidson BK, Kelly CA, Griffiths ID. Ten year follow up of pulmonary function in patients with primary Sjögren's syndrome. Ann Rheum Dis. 2000;59:709-12
31. Dawson LJ, Caulfield VL, Stanbury JB, et al Hydroxychloroquine therapy in patients with primary Sjögren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology (Oxford). 2005;44:449-55
32. Delalande S, de Seze J, Fauchais AL. Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore). 2004;83:280-91
33. Denislic M, Meh D. Early asymmetric neuropathy in primary Sjögren's syndrome. J Neurol. 1997;244(6):383-7
34. Drosos AA, Voulgari PV, Psychos DN, Tsifetaki N, Bai M. Sicca syndrome in patients with sarcoidosis. Rheumatol Int. 1999;18: 177-80
35. Dyck PJ. The clinical heterogeneity of immune sensory and autonomic neuropathies with (or without) sicca. Brain. 2005;128(Pt 11): 2480-2
36. Ferreira S, D'Cruz DP, Hughes GR. Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Rheumatology (Oxford). 2005;44:434-42
37. Font J, Ramos-Casals M, Cervera R, et al Antineutrophil cytoplasmic antibodies in primary Sjögren's syndrome: prevalence and clinical significance. Br J Rheumatol. 1998;37(12):1287-91
38. Font J, Ramos-Casals M, de la Red G, et al Pure sensory neuropathy in primary Sjögren's syndrome. Longterm prospective followup and review of the literature. J Rheumatol. 2003;30(7):1552-7
39. Forstot JZ, Forstot SL, Greer RO, Tan EM. The incidence of Sjögren's sicca complex in a population of patients with keratoconjunctivitis sicca. Arthritis Rheumat. 1982;25:156-60
40. Fox RI, Stern M. Sjögren's syndrome: mechanisms of pathogenesis involve interaction of immune and neurosecretory systems. Scand J Rheumatol Suppl 2002;(116):3-13
41. Franquet T, Diaz C, Domingo P, et al Air trapping in primary Sjögren syndrome: correlation of expiratory CT with pulmonary function tests. J Comput Assist Tomogr. 1999;23:169-73
42. Freeman SR, Sheehan PZ, Thorpe MA, Rutka JA. Ear, nose, and throat manifestations of Sjögren's syndrome: retrospective review of a multidisciplinary clinic. J Otolaryngol. 2005;34(1):20-4
43. García-Carrasco M, Ramos-Casals M, et al Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore). 2002a;81(4):270-80
44. García-Carrasco M, Sisó A, Ramos-Casals M, et al Raynaud's phenomenon in primary Sjögren's syndrome. Prevalence and clinical characteristics in a series of 320 patients. J Rheumatol. 2002b;29: 726-30
45. Gerli R, Muscat C, Giansanti M, et al Quantitative assessment of salivary gland infl ammatory infi ltration in primary Sjögren's syndrome: its relationship to different demographic, clinical and serological features of the disorder. Br J Rheumatol. 1997;36:969-75
46. Goransson LG, Herigstad A, Tjensvoll AB, et al Peripheral neuropathy in primary Sjögren syndrome: a population-based study. Arch Neurol. 2006;63:1612-5
47. Gorson KC, Ropper AH. Muscle Nerve 2003; 28(5):553-60.
48. Positive salivary gland biopsy, Sjögren syndrome, and neuropathy: clinical implications Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 2007; 35(1):66-9
49. Goules A, Masouridi S, Tzioufas AG, et al Clinically significant and biopsy-documented renal involvement in primary Sjögren's syndrome. Medicine (Baltimore). 2000;79:241-9
50. Hakansson U, Jacobsson L, Lilja B, et al Salivary gland scintigraphy in subjects with and without symptoms of dry mouth and/or eyes, and in patients with primary Sjögren's syndrome. Scand J Rheumatol. 1994;23:326-33
51. Helman J, Turner RJ, Fox PC, Baum BJ. 99mTc-pertechnetate uptake in parotid acinar cells by the Na + /K + /Cl- co- transport system. J Clin Invest. 1987;79:1310-3
52. Hernandez YL, Daniels TE. Oral candidiasis in Sjögren's syndrome: prevalence, clinical correlations, and treatment. Oral Surg Oral Med Oral Pathol. 1989;3:324-9
53. Hershkovich O, Shafat I, Nagler RM. Age-related changes in salivary antioxidant profi le: possible implications for oral cancer. J Gerontol A Biol Sci Med Sci. 2007;62:361-6
54. Hyer S, Kong A, Pratt B, et al Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol (R Coll Radiol). 2007;19: 83-6
55. Ioannidis JP, Moutsopoulos HM. Sjögren's syndrome: too many associations, too limited evidence. The enigmatic example of CNS involvement. Semin Arthritis Rheum. 1999;29:1-3
56. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum. 2002;46:741-7
57. Jacobsson LT, Axell TE, Hansen BU, et al Dry eyes or mouth: an epidemiological study in Swedish adults, with special reference to primary Sjögren's syndrome. J Autoimmun. 1989;2:521-7
58. Jara LJ, Navarro C, Brito-Zeron P, et al Thyroid disease in Sjögren's syndrome. Clin Rheumatol. 2007;26:1601-6
59. Jungehulsing M, Fischbach R, Schroder U, et al Magnetic resonance sialography. Otolaryngol Head Neck Surg. 1999;121:488-94
60. Kamisawa T, Okamoto A. Autoimmune pancreatitis: proposal of IgG4- related sclerosing disease. J Gastroenterol. 2006;41:613-25
61. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, Costa J, Decker JL, Chused TM. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978;89:888-92
62. Kohler PF, Winter ME. A quantitative test for xerostomia. The Saxon test, an oral equivalent of the Schirmer test. Arthritis Rheum 1985; 28:1128-32
63. Kohn WG, Ship JA, Atkinson JC, et al Salivary gland 99mTc-scintigraphy: a grading scale and correlation with major salivary gland fl ow rates. J Oral Pathol Med. 1992;21:70-4
64. Krieg AM, Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev. 2007;220:251-69
65. Kruize AA, Hené RJ, Kallenberg CG, et al Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year, double-blind crossover trial. Ann Rheum Dis. 1993;52:360-4
66. Kruize AA, Hene RJ, van der Heide A, Bodeutsch C, deWilde PCM, vanBijsterveld OP, et al Long-term followup of patients with Sjögren's syndrome. Arthritis Rheum. 1996;297-303
67. Lamour A, Le Corre R, Pennec YL, Cartron J, Youinou P. Heterogeneity of neutrophil antibodies in patients with primary Sjögren's syndrome. Blood. 1995;86:3553-9
68. Larsson X, Bredberg A, Henriksson G, Manthorpe R, Sallmyr A. Immunohistochemistry of the B cell component in lower lip salivary glands of Sjögren's syndrome and healthy subjects. Scand J Immunol. 2005;61:98-107
69. Lekhanont K, Leyngold IM, Suwan-Apichon O, et al Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin B-induced mouse model. Cornea. 2007;26: 84-9
70. Leppilahti M, Tammela TL, Huhtala H, et al Interstitial cystitis-like urinary symptoms among patients with Sjögren's syndrome: a population- based study in Finland. Am J Med. 2003;115:62-5
71. Liang L, Zhang M, Zou W, Liu Z. Aggravated dry eye after laser in situ keratomileusis in patients with Sjögren syndrome. Cornea. 2008;27: 120-3
72. Makula E, Pokorny G, Kiss M, et al The place of magnetic resonance and ultrasonographic examinations of the parotid gland in the diagnosis and follow-up of primary Sjögren's syndrome. Rheumatology (Oxford). 2000;39:97-104
73. Maltsman-Tseikhin A, Moricca P, Niv D. Burning mouth syndrome: will better understanding yield better management? Pain Pract. 2007; 7:151-62
74. Mandl T, Ekberg O, Wollmer P, et al Dysphagia and dysmotility of the pharynx and oesophagus in patients with primary Sjögren's syndrome. Scand J Rheumatol. 2007a;36:394-401
75. Mandl T, Wollmer P, Manthorpe R, Jacobsson LT. Autonomic and orthostatic dysfunction in primary Sjögren's syndrome. J Rheumatol. 2007b;34:1869-74
76. Manoussakis MN, Georgopoulou C, Zintzaras E, et al Sjögren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profi les and comparison with primary Sjögren's syndrome. Arthritis Rheum. 2004;50:882-91
77. Mariette X, Agbalika F, Zucker-Franklin D, et al Detection of the tax gene of HTLV-I in labial salivary glands from patients with Sjögren's syndrome and other diseases of the oral cavity. Clin Exp Rheumatol. 2000;18:341-7
78. Mariette X, Ravaud P, Steinfeld S, et al Inefficacy of infl iximab in primary Sjögren's syndrome: results of the randomized, controlled trial of remicade in primary Sjögren's syndrome (TRIPSjS). Arthritis Rheum. 2004;50:1270-6
79. Mariette X, Roux S, Zhang J, et al The level of BlyS (BAFF) correlates with the titer of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis. 2003;62:168-71
80. Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjögren's syndrome. Nat Clin Pract Rheumatol. 2006;2: 252-61
81. Mellgren SI, Goransson LG, Omdal R. Primary Sjögren's syndrome associated neuropathy. Can J Neurol Sci. 2007;34:280-7
82. Mikulicz J. Über eine eigenartige symmetrische Erkrankung der Tranen und Mundspeicheldrusen. Stuttgart: Beitr Chir Fortsch Gewidmet Theodor Billroth. 1892;610-30
83. Mitsias D, Tzioufas A, Veiopoulou C, et al The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjögren's syndrome. Clin Exp Immunol. 2002;128:562-8
84. Mori K, Iijima M, Sugiura M et al Sjögren's syndrome associated painful sensory neuropathy without sensory ataxia. J Neurol Neurosurg Psychiatry 2003; 74(9):1320-2
85. Mori K, Iijima M, Koike H, et al The wide spectrum of clinical manifestations in Sjögren's syndrome-associated neuropathy. Brain. 2005;128:2518-34
86. Moutsopoulos HM, Balow JE, Lawley TJ, et al Immune complex glomerulonephritis in sicca syndrome. Am J Med. 1978;64:955-60
87. Moutsopoulos HM, Elkon KB, Mavridis AK, et al Serum C-reactive protein in primary Sjögren's syndrome. Clin Exp Rheumatol. 1983a;1:57-8
88. Moutsopoulos HM, Webber BL, Vlagopoulos TP, et al Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis. Am J Med. 1979;66:733-6
89. Moutsopoulos HM, Steinberg AD, Fauci AS, et al High incidence of free monoclonal lambda light chains in the sera of patients with Sjögren's syndrome. J Immunol. 1983b;130:2663-5
90. Moutsopoulos HM, Costello R, Drosos AA, et al Demonstration and identification of monoclonal proteins in the urine of patients with Sjögren's syndrome. Ann Rheum Dis. 1985;44:109-12
91. Nagler RM. Salivary glands and the aging process: mechanistic aspects, health-status and medicinal-efficacy monitoring. Biogerontology. 2004;5:223-33
92. Nakamura H, Kawakami A, Tominaga M, et al Relationship between Sjögren's syndrome and human T-lymphotropic virus type I infection: follow-up study of 83 patients. J Lab Clin Med. 2000;135: 139-44
93. Nardi N, Brito-Zerón P, Ramos-Casals M, et al Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjögren's syndrome: prevalence and clinical significance in 335 patients. Clin Rheumatol. 2006;25(3):341-6
94. Papiris SA, Maniati M, Constantopoulos SH, et al Lung involvement in primary Sjögren's syndrome is mainly related to the small airway disease. Ann Rheum Dis. 1999;58:61-4
95. Paschides CA, Kitsios G, Karakostas KX, et al Evaluation of tear break-up time, Schirmer's-I test and rose bengal staining as confi rmatory tests for keratoconjunctivitis sicca. Clin Exp Rheumatol. 1989;7:155-7
96. Patton LL, Siegel MA, Benoliel R, De Laat A. Management of burning mouth syndrome: systematic review and management recommendations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103 Suppl:S39.e1-13
97. Pavlidis NA, Karsh J, Moutsopoulos HM. The clinical picture of primary Sjögren's syndrome: a retrospective study. J Rheumatol. 1982;9: 685-90
98. Pertovaara M, Pukkala E, Laippala P, et al A longitudinal cohort study of Finnish patients with primary Sjögren's syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis. 2001; 60:467-72
99. Pflugfelder SC, Maskin SL, Anderson B, et al A randomized, doublemasked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004 138: 444-57
100. Pillemer SR, Smith J, Fox PC, Bowman SJ. Outcome measures for Sjögren's syndrome. J Rheumatol. 2005;32:143-9
101. Prochorec-Sobieszek M, Wagner T, Loukas M, Chwali ska-Sadowska H, Olesi ska M. Histopathological and immunohistochemical analysis of lymphoid follicles in labial salivary glands in primary and secondary Sjögren's syndrome. Med Sci Monit. 2004;10: BR115-21
102. Ramos-Casals M, Anaya JM, García-Carrasco M, et al Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical signifi - cance of 52 patients. Medicine (Baltimore). 2004a;83(2): 96-106
103. Ramos-Casals M, Font J, Garcia-Carrasco M, et al Primary Sjögren syndrome: hematologic patterns of disease expression. Medicine (Baltimore). 2002;81(4):281-92
104. Ramos-Casals M, García-Carrasco M, Cervera R, et al Thyroid disease in primary Sjögren syndrome: study in a series of 160 patients. Medicine (Baltimore). 2000;79(2):103-8
105. Ramos-Casals M, la Civita L, De Vita S, et al For the SjS-HCV Study Group. Characterization of B cell lymphoma in patients with Sjögren's syndrome and hepatitis C virus infection. Arthritis Rheum. 2007;57(1):161-70
106. Ramos-Casals M, Loustaud-Ratti V, De Vita S, et al For the Sjögren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases. Medicine (Baltimore). 2005;84(2):81-9
107. Ramos-Casals M, Nardi N, Brito-Zerón P, et al Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum. 2006a; 35(5): 312-21
108. Ramos-Casals M, Sánchez-Tapias JM, Parés A, et al Characterization and differentiation of autoimmune versus viral liver involvement in patients with Sjögren's syndrome. J Rheumatol. 2006b;33(8): 1593-9
109. Ramos-Casals M, Solans R, Rosas J, et al Primary Sjögren syndrome in Spain: clinical and immunologic expression of 1010 patients. Medicine (Baltimore). 2008;87(4):210-9
110. Reinertsen JL, Schaefer EJ, Brewer HB, Moutsopoulos HM. Sicca-like syndrome in type V hyperlipoproteinemia. Arthritis Rheum. 1980;23: 114-8
111. Rhodus NL, Michalowicz BS. Periodontal status and sulcular Candida albicans colonization in patients with primary Sjögren's syndrome. Quintessence Int. 2005;36(3):228-33
112. Salliot C, Gottenberg JE, Bengoufa D, et al Anticentromere antibodies identify patients with Sjögren's syndrome and autoimmune overlap syndrome. J Rheumatol. 2007;34(11):2253-8
113. Sankar V, Brennan MT, Kok MR, et al Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50:2240-5
114. Simon BG, Moutsopoulos HM. Primary amyloidosis resembling sicca syndrome. Arthritis Rheum. 1979;22:932-4
115. Sjögren's Syndrome Foundation. And the survey says. The Moisture Seekers. 2006;24:1-3
116. Skopouli FN, Barbatis C, Moutsopoulos HM. Liver involvement in primary Sjögren's syndrome. Br J Rheumatol. 1994a;33:745-8
117. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum. 2000;29:296-304
118. Skopouli FN, Papanikolaou S, Malamou-Mitsi V, et al Obstetric and gynaecological profi le in patients with primary Sjögren's syndrome. Ann Rheum Dis. 1994b;53:569-73
119. Skopouli FN, Talal A, Galanopoulou V, et al Raynaud's phenomenon in primary Sjögren's syndrome. J Rheumatol. 1990;17:618-20
120. Stevens WJ, Swartele FE, Empsten FA, De Clerck LS. Use of the Saxon test as a measure of saliva production in a reference population of schoolchildren. Am J Dis Child. 1990;144:570-1
121. Stojanovich L, Milovanovich B, de Luka SR, et al Cardiovascular autonomic dysfunction in systemic lupus, rheumatoid arthritis, primary Sjögren syndrome and other autoimmune diseases. Lupus. 2007;16: 181-5
122. Takeda S, Haratake J, Kasai T, et al IgG4-associated idiopathic tubulointerstitial nephritis complicating autoimmune pancreatitis. Nephrol Dial Transplant. 2004;19:474-6
123. Taouli B, Brauner MW, Mourey I, et al Thin-section chest CT findings of primary Sjögren's syndrome: correlation with pulmonary function. Eur Radiol. 2002;12:1504-11
124. Terrier B, Lacroix C, Guillevin L, et al Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sjögren's syndromerelated neuropathy. Arthritis Rheum. 2007;57(8):1520-9
125. Theander E, Manthorpe R, Jacobsson L. Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study. Arthritis Rheum. 2004;50:1262-9
126. Tishler M, Yaron I, Shirazi I, Yaron M. Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum infl ammatory markers. Ann Rheum Dis. 1999;58:253-6
127. Trontzas PI, Andrianakos AA. Sjögren's syndrome: a population based study of prevalence in Greece. Ann Rheum Dis. 2005;64:1240-1
128. Tsampoulas CG, Skopouli FN, Sartoris DJ, et al Hand radiographic changes in patients with primary and secondary Sjögren's syndrome. Scand J Rheumatol. 1986;15:333-9
129. Tsianos EB, Chiras CD, Drosos AA, Moutsopoulos HM. Oesophageal dysfunction in patients with primary Sjögren's syndrome. Ann Rheum Dis. 1985;44:610-3
130. Tsianos EB, Tzioufas AG, Kita MD, et al Serum isoamylases in patients with autoimmune rheumatic diseases. Clin Exp Rheumatol. 1984;2: 235-8
131. Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. Arthritis Rheum. 1996;39:767-72
132. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum. 1993;36: 340-7
133. Vitali C, Bombardieri S, Moutsopoulos HM, Coll J, Gerli R, Hatron Y, et al Assessment of the European classification criteria for Sjogren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. Ann Rheum Dis. 1996;55:116-21
134. Vitali C, Bombardieri Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American- European consensus group. Ann Rheum Dis. 2002;61:544-58
135. Vivino FB, Gala I, Hermann GA. Change in final diagnosis on second evaluation of labial minor salivary gland biopsies. J Rheumatol. 2002;29:938-44
136. Voulgarelis M, Dafni UG, Isenberg DA, Mousopoulos HM. Malignant lymphoma in primary Sjögren's syndrome. A multicenter, retrospective, clinical study by the European concerted action on Sjögren's syndrome. Arthritis Rheum. 1999;42:1765-72
137. Voulgarelis M, Giannouli S, Tzioufas AG, Moutsopoulos HM. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis. 2006;65:1033-7
138. Walker J, Gordon T, Lester S, et al Increased severity of lower urinary tract symptoms and daytime somnolence in primary Sjögren's syndrome. J Rheumatol. 2003;30:2406-12
139. Whitcher J, Gritz D, Daniels T. The dry eye: a diagnostic dilemma. Int Ophthal Clin. 1998;38:23-37
140. Wolkoff P, Nojgaard JK, Franck C, Skov P. The modern office environment desiccates the eyes? Indoor Air. 2006;16:258-65
141. Wright SA, Convery RP, Liggett N. Pulmonary involvement in Sjögren's syndrome. Rheumatology (Oxford). 2003;42:697-8
142. Wu AJ, Fox PC. Sjögren's syndrome. Semin Dermatol. 1994;13:138-43
143. Yamamoto M, Takahashi H, Sugai S, Imai K. Clinical and pathological characteristics of Mikulicz's disease (IgG4-related plasmacytic exocrinopathy). Autoimmun Rev. 2005;4:195-200
144. Zandbelt MM, de Wilde P, van Damme P, et al Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study. J Rheumatol. 2004;31:96-101
145. Zintzaras E, Voulgarelis M, Moutsopoulos H. The risk of lymphoma development in autoimmune diseases. Arch Intern Med. 2005; 165:2337-44
146. Klippel JH, Stone JS, Crofford L, White P. Primer on the Rheumatic Diseases. 13th Edition. 2008. Springer. London